Literature DB >> 15338451

Levels of soluble E-selectin in patients with active Behcet's disease.

Refik Ali Sari1, Ahmet Kiziltunç, Seyithan Taysi, Seyithan Taysý, Serpil Akdemir, Serpil Akdemýr, Mehmet Gündoğdu.   

Abstract

Behcet's disease is a systemic vasculitis of unknown aetiology. Endothelial cell injury plays an important role in the pathogenesis and immunopathology of Behcet's disease. E-selectin is expressed by activated endothelial cells. Because the selectin adhesion molecules are shed from activated cells, soluble forms of these proteins can be used as activation markers of endothelium (E-selectin). The pathogenesis of Behcet's disease (BD) is closely related to endothelial cells, leucocyte functions and immunity. The aim of this study was to investigate circulating E-selectin adhesion molecules, which are known to play a significant part in the immune response especially by regulating interaction of the leucocytes with endothelium in BD. Plasma E-selectin concentrations were evaluated in 23 patients with BD and 20 healthy control subjects. The disease activity was evaluated by clinical manifestations (oral aphthous ulcer, genital ulceration, positive pathergy test, skin lesions, eye involvement, thrombophlebitis and arthritis) and by laboratory investigations [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)]. The patients were newly or previously diagnosed cases not taking any drug for BD. Levels of E-selectin were measured with commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kits using human sE-selectin (cat. no: BMS 205). Plasma E-selectin concentrations of patients and controls were compared with the Mann-Whitney U test. Statistical significance was assigned to p values lower than 0.05. Serum levels (mean+/-SD) of soluble E-selectin (sE-selectin) were significantly higher in 23 patients with BD than in 20 healthy controls (53.2+/-18.2 ng/ml vs 33.8+/-7.5 ng/ml, p<0.0001). A statistically significant positive correlation was observed between sE-selectin levels and CRP and ESR in patients with BD (r=0.78, p<0.001 and r=0.56, p<0.01, respectively). Increases in the E-selectin in BD may be a direct consequence of the leucocyte and endothelium activations observed during the disease process. The noninvasive investigations can be used as biochemical markers for inflammation. This may provide additional information regarding disease activity along with the traditional indices such as ESR and CRP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338451     DOI: 10.1007/s10067-004-0982-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  Serum-soluble selectin levels in patients with Behçet's disease.

Authors:  Aşkin Ateş; Olcay Aydintuğ Tiryaki; Umit Olmez; Hüseyin Tutkak
Journal:  Clin Rheumatol       Date:  2007-01-06       Impact factor: 2.980

2.  Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling.

Authors:  M T Lee; L C Hooper; L Kump; K Hayashi; R Nussenblatt; J J Hooks; B Detrick
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 3.  Cardiovascular disease in patients with autoinflammatory syndromes.

Authors:  Rainer Hintenberger; Agnes Falkinger; Kathrin Danninger; Herwig Pieringer
Journal:  Rheumatol Int       Date:  2017-11-01       Impact factor: 2.631

4.  Behçet's Disease as a Model of Venous Thrombosis.

Authors:  Micaela La Regina; Armen Yuri Gasparyan; Francesco Orlandini; Domenico Prisco
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

Review 5.  Behcet's Syndrome.

Authors:  Sam R Dalvi; Resit Yildirim; Yusuf Yazici
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

Review 6.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

7.  Behcet's Disease: New Concepts in Cardiovascular Involvements and Future Direction for Treatment.

Authors:  M B Owlia; G Mehrpoor
Journal:  ISRN Pharmacol       Date:  2012-03-08

8.  Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behçet's disease.

Authors:  Federica Delunardo; Fabrizio Conti; Paola Margutti; Cristiano Alessandri; Roberta Priori; Alessandra Siracusano; Rachele Riganò; Elisabetta Profumo; Guido Valesini; Maurizio Sorice; Elena Ortona
Journal:  Arthritis Res Ther       Date:  2006-04-12       Impact factor: 5.156

9.  Thrombosis in vasculitis: from pathogenesis to treatment.

Authors:  Giacomo Emmi; Elena Silvestri; Danilo Squatrito; Amedeo Amedei; Elena Niccolai; Mario Milco D'Elios; Chiara Della Bella; Alessia Grassi; Matteo Becatti; Claudia Fiorillo; Lorenzo Emmi; Augusto Vaglio; Domenico Prisco
Journal:  Thromb J       Date:  2015-04-16

10.  Evaluation of atherogenic laboratory markers in Behçet's disease patients with vascular involvement.

Authors:  Çiğdem Yücel; Ahmet Omma; Erdim Sertoğlu; Sevilay Sezer; Turan Turhan; Taner Özgürtaş
Journal:  Arch Med Sci       Date:  2019-10-27       Impact factor: 3.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.